包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2Dbmolecules at the RMA-S (Db Kb) cell surface with a SC50of 344 nM[1]. | ||||||||||||||||
体外研究 (In Vitro) | GP(33-41) TFA sensitizes MC57 and T2-Dbcells to lysis with ED50s of 0.9±0.6 and 2.5±0.7 nM[1].The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D[2]. | ||||||||||||||||
分子量 | 1130.19 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C48H70F3N11O15S | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 1.82 mg/mL(1.61 mM;ultrasonic and adjust pH to 4 with HCl) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |